Jeffrey Woldt
Health Equity Summit panel tackles pharmacy deserts
Chain Drug Review and Kearney hosted their third annual Health Equity Summit in Chicago, where a panel of experts discussed the prevalence of pharmacy deserts, affecting millions of Americans, and strategies to address these disparities.
Health Equity Summit 3.0 – Part 1
This is the first in a series of videos that will present highlights from the event. Here are excerpts from remarks by keynote speaker Rina Shah, senior vice president of pharmacy growth at Walgreens.
Video Forum: Michelle LeBlanc, CVS Health
Bringing a fresh perspective to beauty and personal care.
Video Forum: J.W. Hill, National Council for Prescription Drug Programs
Moving health information technology forward.
Health Equity 3.0
In her keynote address, Rina Shah, senior vice president of pharmacy growth at Walgreens, described how health equity emerged as a central consideration in the drug chain’s strategic planning process and what that means going forward
It’s time to rethink the drug store model
Reimbursements have declined to a point at which pharmacies lose money when they fill some scripts.
Flawed health system needs overhaul
“The U.S. is failing one of its principal obligations as a nation: to protect the health and welfare of its people,” says Dr. Joseph Betancourt, president of the Commonwealth Fund.
Video Forum: John Carroll, Acosta Group
Digital tools rewrite rules for retailers, CPG companies.
Health care gravitates toward retail setting
During an Insight Session at last month’s NACDS Total Store Expo in Boston, O’Connor discussed how the manner in which buyers and sellers interact will evolve at an ever-accelerating rate.
Rite Aid's new beginning: an interview with CEO Matt Schroeder
Rite Aid's new CEO shares that the company will build on the retailer’s iconic brand and standing as a trusted health care provider.
Video Forum: Dr. Vin Gupta, Amazon Pharmacy
E-commerce powerhouse offers an alternative for Rx patients.
PBM reform: The end of the beginning
The recent release of an interim report by the Federal Trade Commission about what the agency characterizes as “prescription drug middlemen” represents a vindication of sorts for pharmacy advocates who have long contended that PBMs employ business practices that skew the market to their advantage.